Epidemiology of skin cancer in the mature patient

Lai, Vivien Wai Yun; Cranwell, William; Sinclair, Rodney

doi:10.1016/j.clindermatol.2017.10.008

Cited by 116 publications

(83 citation statements)

References 120 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patient‐reported outcome measures (PROMs) offer potential to improve the quality of dermatology services in the National Health Service (NHS) by providing validated evidence from the patient perspective. The incidence of non‐melanoma skin cancers (NMSCs) is exponentially increasing and although rarely life‐threatening, both disease and treatments can have significant impact on health‐related quality of life (HRQOL) . Evaluating PROMs in NMSC is essential because of the impact on health and the burden on healthcare resources, yet there are few studies to date.…”

Section: Introductionmentioning

confidence: 99%

Use of the Skin Cancer Quality of Life Impact Tool (SCQOLIT) – a feasibility study in non‐melanoma skin cancer

Wali

Gibbons

Kelly

et al. 2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

Background Incidence of non‐melanoma skin cancers (NMSCs) is increasing and can significantly impact on quality of life (QOL), yet there are few studies evaluating patient‐reported outcome measures (PROMs) in NMSC populations. We undertook a prospective feasibility study to evaluate a skin cancer‐specific PROM, the Skin Cancer Quality of Life Impact Tool (SCQOLIT), in patients with a new diagnosis of NMSC. Objectives (i) To establish acceptability of SCQOLIT in dermatology clinics, (ii) a descriptive analysis of SCQOLIT scores in NMSC. Methods Patients with histologically confirmed NMSC completed SCQOLIT, EQ‐5D and a transition item. Questionnaires were completed at baseline and 3 months for group 1 (‘low‐risk’ NMSC) and group 2 (‘high‐risk’ NMSC) with additional questionnaires at 6–9 months for group 2. Patients participated in structured interviews. Clinician experience was captured through staff evaluation forms and a focus group. Acceptability and psychometric properties of SCQOLIT were assessed. Results Overall, 318 patients consented to participate. Mean SCQOLIT score at baseline was 5.33, with 2.6% of patients scoring ≥20. No ceiling effects were observed, whilst 13.9% scored 0. Validity was demonstrated against EQ‐5D. Cronbach's alpha 0.84 demonstrated internal consistency. Thirteen patients were interviewed and thought SCQOLIT was comprehensive, captured impact on health‐related QOL and helped express their needs to clinicians. Most clinicians found SCQOLIT ‘very useful’ or ‘useful to some extent’ in facilitating discussions. Conclusions This feasibility study demonstrates that SCQOLIT is acceptable to patients and staff in dermatology skin cancer clinics. The psychometric properties of SCQOLIT confirm its utility in NMSC populations.

show abstract

Section: Introductionmentioning

confidence: 99%

Use of the Skin Cancer Quality of Life Impact Tool (SCQOLIT) – a feasibility study in non‐melanoma skin cancer

Wali

Gibbons

Kelly

et al. 2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Australia has the highest number of skin cancers in the world. 4 Nonmelanoma skin cancer (NMSC) is the most common type of cancer in Australia and its incidence is increasing. 5 In this country, NMSC accounts for the second highest cancer expenditure after colorectal cancer.…”

Section: Discussionmentioning

confidence: 99%

Volumetric modulated arc therapy (VMAT) for skin field cancerisation of the nose - A technique and case report

Fogarty¹,

Martin²,

Moutrie³

et al. 2018

IJRRT

View full text Add to dashboard Cite

Locally advanced skin cancer of the nose is problematic, especially when all nasal skin needs treatment as in the case of skin field cancerisation (SFC). Surgery is considered the gold standard but involves tissue loss which may impact function and cosmesis. In patients who are not good surgical candidates, definitive radiotherapy (RT) can be used.Traditional RT modalities for the nose, such as brachytherapy, superficial x-ray treatment or electrons, have quality assurance issues and can be difficult to conform to the target volume. Volumetric modulated arc therapy (VMAT) is an advanced form of intensity modulated radiotherapy (IMRT). IMRT confines the high dose of radiation to the tumour and is used to avoid irradiating a dose-sensitive structure in the concavity of a volume that requires a therapeutic dose for tumour control. Within the nose, the nasal septum is a dose-limiting structure in the concavity of the skin covering the nose.We present here a case report using a VMAT technique to treat SFC of the nose. To our knowledge, this is the first description in the literature of VMAT for SFC of the nose. We also believe it to be the first time that VMAT simultaneous integrated boost (SIB) to biopsy proven macroscopic disease has been used when treating SFC.

show abstract

“…Skin cutaneous melanoma (SKCM) acts as a common skin malignancy around the world [1]. It was estimated that 287,723 new cases and 60,712 cancer-related deaths occurred in 2018 [2].…”

Section: Introductionmentioning

confidence: 99%

Development and Validation of An Immune-Related Gene Pair Signature in Skin Cutaneous Melanoma

Xie¹,

Dong²,

Jiang

et al. 2020

Preprint

View full text Add to dashboard Cite

Skin cutaneous melanoma (SKCM) is a common skin malignancy worldwide, and its metastasis and mortality rates are high. The molecular characteristics exhibited by tumor-immune interactions have drawn the attention from researchers. Therefore, increased knowledge and new strategies to identify effective immune-related biomarkers may improve the clinical management of SKCM by providing more accurate prognostic information. In this study, we established a prognostic immune-related gene pair (IRGP) signature for predicting the survival of SKCM patients. The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases provided gene expression profiles together with clinical information, and the samples were randomly divided into three groups including the training, testing, and validation datasets. The regression model of least absolute shrinkage and selection operator (LASSO) helped to identify a 13-IRGP signature with a significant relation to the survival of SKCM patients. The training, TCGA, and independent sets have an average value of area under the curve of 0.79, 0.76, and 0.82, respectively. In addition, this 13-IRGP signature can noticeably divide SKCM patients into high-risk group and low-risk group with significantly different prognoses. Many biological activities such as gene family were enriched among the genes in our IRGP signature. While analyzing the risk signature and clinical characteristics, there was a large difference in the risk score between T stage and tumor stage grouping. Finally, we constructed a nomogram and forest plots of the risk score and clinical features. In summary, we developed a robust 13-IRGP prognostic signature in SKCM, which can identify and provide new insights into immunological biomarkers.

show abstract

Epidemiology of skin cancer in the mature patient

Cited by 116 publications

References 120 publications

Use of the Skin Cancer Quality of Life Impact Tool (SCQOLIT) – a feasibility study in non‐melanoma skin cancer

Use of the Skin Cancer Quality of Life Impact Tool (SCQOLIT) – a feasibility study in non‐melanoma skin cancer

Volumetric modulated arc therapy (VMAT) for skin field cancerisation of the nose - A technique and case report

Development and Validation of An Immune-Related Gene Pair Signature in Skin Cutaneous Melanoma

Contact Info

Product

Resources

About